IL11-mediated stromal cell activation may not be the master regulator of pro-fibrotic signaling downstream of TGFβ

Fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF) and systemic scleroderma (SSc), are commonly associated with high morbidity and mortality, thereby representing a significant unmet medical need. Interleukin 11 (IL11)-mediated cell activation has been identified as a central mechanism f...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Yunhao Tan, Kenta Mosallanejad, Qingxiu Zhang, Stephen O’Brien, Meghan Clements, Stuart Perper, Sarah Wilson, Sudiksha Chaulagain, Jing Wang, Mary Abdalla, Helen Al-Saidi, Danyal Butt, Anca Clabbers, Kwasi Ofori, Beth Dillon, Bohdan Harvey, John Memmott, Christopher Negron, David Winarta, Catherine Tan, Amlan Biswas, Feng Dong, Vanessa Morales-Tirado, Xiaoqing Lu, Gurminder Singh, Michael White, Shanna Ashley, Heather Knight, Susan Westmoreland, Lucy Phillips, Tracy Carr, Lauren Reinke-Breen, Rajeeva Singh, Jianwen Xu, Kan Wu, Lisa Rinaldi, Brian Stoll, Yupeng David He, Lisa Hazelwood, Jozsef Karman, Andrew McCluskey, William Stine, Ivan Correia, Stephen Gauld, Marc C. Levesque, Geertruida Veldman, Cedric Hubeau, Timothy Radstake, Ramkrishna Sadhukhan, Edda Fiebiger
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2024-02-01
Serija:	Frontiers in Immunology
Teme:	IL11 fibrosis drug target STAT3 ERK stromal cell
Online dostop:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1293883/full
Oznake:	Označite Brez oznak, prvi označite!